Equities research analysts forecast that Myomo, Inc. (NASDAQ:MYO) will report ($0.17) earnings per share (EPS) for the current fiscal quarter, according to Zacks Investment Research. Two analysts have provided estimates for Myomo’s earnings. The highest EPS estimate is ($0.15) and the lowest is ($0.18). Myomo posted earnings per share of ($0.21) during the same quarter last year, which would suggest a positive year-over-year growth rate of 19%. The business is expected to announce its next earnings report on Tuesday, August 6th.
According to Zacks, analysts expect that Myomo will report full-year earnings of ($0.64) per share for the current year, with EPS estimates ranging from ($0.69) to ($0.58). For the next year, analysts expect that the company will post earnings of ($0.47) per share, with EPS estimates ranging from ($0.59) to ($0.35). Zacks Investment Research’s EPS averages are an average based on a survey of research firms that that provide coverage for Myomo.
Myomo (NASDAQ:MYO) last released its quarterly earnings data on Monday, May 13th. The company reported ($0.17) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.20) by $0.03. The company had revenue of $0.83 million for the quarter, compared to analysts’ expectations of $0.86 million.
Myomo Company Profile
Myomo, Inc, a commercial stage medical robotics company, designs, develops, and produces myoelectric braces or orthotics for people suffering with neuromuscular disorders in the United States. It offers MyoPro, a powered upper limb orthosis that supports the arm, as well as restores function to the weakened or paralyzed arms of patients suffering from CVA stroke, brachial plexus injury, traumatic brain injury, spinal cord injury, ALS, or other neuromuscular disease or injury.
Featured Story: Producer Price Index (PPI)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Myomo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myomo and related companies with MarketBeat.com's FREE daily email newsletter.